Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mastocytosis
•
Mast Cell Disorders
Does a patient with known systemic mastocytosis need a bone biopsy of lytic vertebral lesions to rule out other etiologies?
Related Questions
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
How do you interpret high C1q binding assay with otherwise normal C1q, C3, C4, CH50 in a patient with recurrent urticaria with positive ANA at high titer 1:1280, negative dsDNA, RNP, SM, normal CBC, CMP, UA, and UPCR.
In those patients who are initiated on omalizumab for multiple food allergies, once baked egg and baked milk are introduced into the diet, do you rely upon skin prick testing and/or ImmunoCAP testing in order to make the decision to introduce prepared egg or whole milk into the diet?
Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?
